Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model

Melanoma is an aggressive cancer with fast metastatic spread and reduced survival time. One common event during the neoplastic progression is the epithelial–mesenchymal transition (EMT), which enhances invasiveness, cell migration, and metastasis. In this study, we investigated the effects of metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Veloso, Emerson Soares, de Carvalho, Bárbara Andrade, de Souza Silva, Felipe Henrique, Ribeiro, Thaís Salviana, Lima, Bruna Mendes, Almeida, Camila Pereira, da Silva, Vítor Henrique Soares Romão, Rocha, Sara Aparecida, de Araújo Campos, Marina Rios, Del Puerto, Helen Lima, Ferreira, Enio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588059/
https://www.ncbi.nlm.nih.gov/pubmed/36273071
http://dx.doi.org/10.1038/s41598-022-22235-8
Descripción
Sumario:Melanoma is an aggressive cancer with fast metastatic spread and reduced survival time. One common event during the neoplastic progression is the epithelial–mesenchymal transition (EMT), which enhances invasiveness, cell migration, and metastasis. In this study, we investigated the effects of metformin at EMT in melanoma cell lines B16-F10 and A-375, in vitro, and the impact of EMT downregulation on melanoma progression in vivo. The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo. These results indicate that metformin can promote EMT downregulation impairing the metastatic potential of melanoma cells.

Ejemplares similares